K. Atwal

发表

Benzodiazepine-based selective inhibitors of mitochondrial F1F0 ATP hydrolase.

L. Hamann, P. Stein, D. Green, 2004, Bioorganic & medicinal chemistry letters.

N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase.

K. J. Yost, Hsinglin Lan, L. Hamann, 2004, Bioorganic & medicinal chemistry letters.

Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0-ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity.

G. Grover, P. Sleph, D. Green, 2004, American journal of physiology. Heart and circulatory physiology.

Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.

J. Yanchunas, K. Kish, H. Klei, 2009, Bioorganic & medicinal chemistry letters.

Aryl cyanoguanidine potassium channel openers

S. Moreland, J. Mccullough, K. Atwal, 1992 .

Cardioprotective Profile of the Cardiac‐Selective ATP‐Sensitive Potassium Channel Opener BMS‐180448

G. Grover, J. Mccullough, C. Sargent, 1995, Journal of cardiovascular pharmacology.

Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers.

A. Mathur, P. Stein, M. Conder, 2001, Journal of Medicinal Chemistry.

Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable IKs blockers

A. Mathur, P. Stein, Mark A. Smith, 2001 .

Glyburide-reversible cardioprotective effects of calcium-independent phospholipase A2 inhibition in ischemic rat hearts.

G. Grover, H. Murray, C. Sargent, 1996, Cardiovascular research.

Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.

M. Kirby, Saleem Ahmad, R. Zahler, 2006, Bioorganic & medicinal chemistry letters.

Advances in the structure‐activity relationships, mechanisms of action, and therapeutic utilities of ATP‐sensitive potassium channel openers

K. Atwal, 1994 .

BMS‐180448, A Glyburide‐Reversible Cardioprotective Agent with Minimal Vasodilator Activity

G. Grover, K. Atwal, 1995 .

Modulation of potassium channels by organic molecules

K. Atwal, 1992, Medicinal research reviews.

Tetrahydronaphthalene-derived amino alcohols and amino ketones as potent and selective inhibitors of the delayed rectifier potassium current IKs.

John Lloyd, Saleem Ahmad, P. Stein, 2004, Bioorganic & medicinal chemistry letters.

Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.

Huabin Sun, Christine S. Huang, M. Conder, 2010, Bioorganic & medicinal chemistry letters.

Benzopyran sulfonamides as KV1.5 potassium channel blockers.

T. Huynh, Wayne Vaccaro, M. Conder, 2007, Bioorganic & medicinal chemistry letters.

Nucleotide regulation and characteristics of potassium channel opener binding to skeletal muscle membranes.

K. Dickinson, D. Green, K. Atwal, 1997, Molecular pharmacology.

(cis)-3-methyl-1,5-benzothiazepine-4-ones: potent analogs of the calcium channel blocker diltiazen

S. Moreland, D. Floyd, A. Hedberg, 1993 .

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.

R. Parker, L. Hamann, M. Kirby, 2007, Bioorganic & medicinal chemistry letters.

Pharmacologic profile of the selective mitochondrial-K(ATP) opener BMS-191095 for treatment of acute myocardial ischemia.

G. Grover, K. Atwal, 2006, Cardiovascular drug reviews.

Aminoimidazoles as bioisosteres of acylguanidines: novel, potent, selective and orally bioavailable inhibitors of the sodium hydrogen exchanger isoform-1.

M. Kirby, Saleem Ahmad, G. Chandrasena, 2004, Bioorganic & medicinal chemistry letters.

Arylcyclopropanecarboxyl guanidines as novel, potent, and selective inhibitors of the sodium hydrogen exchanger isoform-1.

K. J. Yost, M. Kirby, N. Grazier, 2001, Journal of medicinal chemistry.

Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.

P. Lam, J. Macor, E. Liu, 2007, Bioorganic & medicinal chemistry letters.

Pharmacology and Structure‐Activity Relationships for KATP Modulators: Tissue‐Selective KATP Openers

K. Atwal, 1994, Journal of cardiovascular pharmacology.

One-pot synthesis and conformational features of n,n'-disubstituted ketene aminals.

Michael A. Galella, P. Stein, N. Grazier, 2004, The Journal of organic chemistry.

Substituted 1,4-dihydropyrimidines. 3. Synthesis of selectively functionalized 2-hetero-1,4-dihydropyrimidines

G. Rovnyak, K. Atwal, B. C. O'reilly, 1989 .

Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase.

J. Macor, N. Murugesan, Z. Gu, 2005, Bioorganic & medicinal chemistry letters.

Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.

S. Chong, J. Yanchunas, K. Kish, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of acylguanidine FXa inhibitors.

E. Liu, P. Stein, Yan Shi, 2008, Bioorganic & medicinal chemistry letters.

Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.

E. Liu, P. Stein, A. Rendina, 2005, Bioorganic & medicinal chemistry letters.

Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.

Ying Wang, Doree Sitkoff, Jing Zhang, 2011, Bioorganic & medicinal chemistry letters.

Dihydropyrimidine angiotensin II receptor antagonists.

S. Moreland, K. Dickinson, J. E. Bird, 1992, Journal of Medicinal Chemistry.

Synthesis and biological activity of novel calcium channel blockers: 2,5-dihydro-4-methyl-2-phenyl-1,5-benzothiazepine-3-carboxylic acid esters and 2,5-dihydro-4-methyl-2-phenyl-1,5-benzodiazepine-3-carboxylic acid esters.

S. Moreland, J. L. Bergey, A. Hedberg, 1987, Journal of medicinal chemistry.

Acid catalyzed intramolecular conjugate addition as a route to trans hydrindane systems

G. Stork, K. Atwal, 1983 .

A stereospecific synthesis of napelline

T. Y. Tsai, K. Wiesner, K. Atwal, 1980 .

On the stereochemistry of photoaddition between α,β-unsaturated ketones and olefins. III.

J. Blount, T. Y. Tsai, K. Wiesner, 1980 .

On the construction of the C/D ring systems of chasmanine and napelline by diene addition

T. Y. Tsai, I. H. Sánchez, K. Wiesner, 1978 .

A stereospecific synthesis of napelline

T. Y. Tsai, K. Wiesner, K. Atwal, 1980 .

Dihydropyrimidine calcium channel blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents.

A Hedberg, S. Moreland, D. Floyd, 1991, Journal of medicinal chemistry.

Cardioselective anti-ischemic ATP-sensitive potassium channel openers.

S. Moreland, G. Grover, P. Sleph, 1993, Journal of medicinal chemistry.

Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.

S. Moreland, S. D. Kimball, M. Malley, 1992, Journal of medicinal chemistry.

Synthesis of substituted 1,2,3,4-tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic acid esters: the Biginelli condensation revisited

K. Atwal, B. C. O'reilly, 1987 .

Synthesis of substituted 1,2,3,4-tetrahydro-6-methyl-2-thioxo-5-pyrimidinecarboxylic acid esters

M. Malley, J. Gougoutas, K. Atwal, 1987 .

Dihydropyrimidine Calcium Channel Blockers. Part 3. 3‐Carbamoyl‐4‐aryl‐1,2,3,4‐tetrahydro‐6‐methyl‐5‐pyrimidinecarboxylic Acid Esters as Orally Effective Antihypertensive Agents.

S. Moreland, D. Floyd, S. Unger, 1991 .

Dihydropyrimidine calcium channel blockers. 2. 3-substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines.

S. Moreland, D. Floyd, S. D. Kimball, 1990, Journal of medicinal chemistry.

Dihydropyrimidine calcium channel blockers 51: bicyclic dihydropyrimidines as potent mimics of dihydropyridines

S. Moreland, K. Atwal, 1991 .

Dihydropyrimidine calcium channel blockers: 2-heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridines.

S. Moreland, D. Floyd, M. Malley, 1990, Journal of medicinal chemistry.

Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring.

G. Grover, P. Sleph, K. Atwal, 1995, Journal of medicinal chemistry.

Synthesis of Substituted 1,2,3,4-Tetrahydro-6-methyl-2-oxo-5-pyrimidinecarboxylic Acid Esters: The Biginelli Condensation Revisited.

K. Atwal, B. C. O'reilly, 1987 .

Synthesis of Substituted 1,2,3,4-Tetrahydro-6-methyl-2-thioxo-5-pyrimidinecarboxylic Acid Esters.

M. Malley, J. Gougoutas, K. Atwal, 1987 .

Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.

W. Humphreys, G. Grover, P. Sleph, 1997, Journal of medicinal chemistry.

Substituted 1,2,3,4-tetrahydroaminonaphthols: antihypertensive agents, calcium channel blockers, and adrenergic receptor blockers with catecholamine-depleting effects.

S. Moreland, J. Powell, J. L. Bergey, 1987, Journal of medicinal chemistry.

Substituted 1,4-Dihydropyrimidines. Part 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihydropyrimidines.

G. Rovnyak, K. Atwal, B. C. O'reilly, 1990 .

Dihydropyrimidine Calcium Channel Blockers. Part 2. 3-Substituted 4- Aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines.

S. Moreland, D. Floyd, S. D. Kimball, 1991 .

Dihydropyrazolopyrimidine inhibitors of K(V)1.5 (I(Kur)).

T. Huynh, Wayne Vaccaro, M. Conder, 2008, Bioorganic & medicinal chemistry letters.

Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.

Huabin Sun, T. Huynh, Wayne Vaccaro, 2009, Bioorganic & medicinal chemistry letters.

A facile synthesis of cyanoguanidines from thioureas

K. Atwal, B. C. O'reilly, S. Z. Ahmed, 1989 .

An isomerization—claisen rearrangement route to olefinic dicarbonyl starting materials for conjugate cyclization

G. Stork, K. Atwal, 1982 .

Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: replacement of the benzopyran portion.

G. Grover, P. Sleph, C. Ding, 1996, Journal of medicinal chemistry.

Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.

K. Dickinson, G. Grover, P. Sleph, 1998, Journal of medicinal chemistry.

One-pot synthesis of N,N′-disubstituted acylguanidines

P. Stein, Yan Shi, K. Atwal, 2002 .

Phenacein--an angiotensin-converting enzyme inhibitor produced by a streptomycete. II. Isolation, structure determination and synthesis.

W. Parker, W. C. Liu, K. Atwal, 1984, The Journal of antibiotics.

Trimethylaluminum promoted synthesis of cyanoguanidines

K. Atwal, F. N. Ferrara, S. Z. Ahmed, 1994 .

The discovery of a novel calcium channel blocker related to the structure of potassium channel opener cromakalim

M. Conder, J. Mccullough, K. Atwal, 1992 .

Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides.

J. Newburger, G. Grover, P. Sleph, 1991, The Journal of pharmacology and experimental therapeutics.

Benzopyranyl-cyanoguanidine potassium channel openers

S. Moreland, J. Mccullough, K. Atwal, 1992 .

Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.

M. Blanar, M. Conder, J. Lloyd, 2013, Bioorganic & medicinal chemistry letters.

Triphenylphosphine oxide is a potent and selective inhibitor of the transient receptor potential melastatin-5 ion channel.

R. Cortés, D. Sprous, M. Buber, 2010, Assay and drug development technologies.

Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.

G. Grover, P. Sleph, N. Lodge, 2001, The Journal of pharmacology and experimental therapeutics.

Pyrano-[2,3b]-pyridines as potassium channel antagonists.

M. Conder, J. Lloyd, P. Levesque, 2008, Bioorganic & medicinal chemistry letters.

Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.

Jing Zhang, Doree Sitkoff, Kevin Kish, 2008, Journal of medicinal chemistry.

Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.

M. Blanar, M. Conder, J. Lloyd, 2013, Bioorganic & medicinal chemistry letters.